BOSTON, MA–(Marketwired – Jan 10, 2014) – Solos Endoscopy, Inc. (OTC Pink: SNDY) a provider of quality innovative healthcare instruments to Hospitals across the Country, posted an update for the shareholders on OTC Markets.com.
The Company posted a letter from the President on the OTC Markets website (http://www.otcmarkets.com/financialReportViewer?symbol=SNDYid=115342)
Solos Endoscopy completed the Audit with TUV SUD America this past year, which included a comprehensive review of the Solos Endoscopy’s Quality Manual and 28 Quality System Procedures for compliance with the international quality system standard ISO 13485:2003, to the European Union’s Medical Device Directive (MDD 93/42/EEC) and to the Canadian Medical Device Regulations (SOR/98-282). Since the completion of the Audit, the Company has been in contact with the representatives from both TUV SUD and Expert Resources and expects to be certified to ISO 13485:2003 in the next few weeks. Certification to ISO 13485:2003 will in turn allow Solos Endoscopy to obtain the CE Mark on the majority of endoscopic instruments including the MammoView® devices.
Solos has several exciting new advances in product development that will change the way minimally invasive procedures are utilized in the medical field in order to treat and prevent disease. These products will allow the physician to examine organs and tissues within the body without the need for intrusive surgery. The Company is currently marketing its next generation breast endoscopy system, the MammoView® system, for early breast cancer detection.
About Solos Endoscopy, Inc.:
Solos Endoscopy celebrated its 25th Year of providing quality innovative healthcare instruments to Hospitals across the Country. For more than 25 Years, from medical schools to hospitals, surgeons have trusted Solos Endoscopy to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Additional information on its FDA approved products is available on the Company’s website at: www.solosendoscopy.com.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company’s Annual Report filing and other filings with the OTC Markets Group (available at www.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.